These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 35116427)
21. An Effective Hypoxia-Related Long Non-Coding RNA Assessment Model for Prognosis of Lung Adenocarcinoma. Li Y; Sun X Front Genet; 2022; 13():768971. PubMed ID: 35368654 [No Abstract] [Full Text] [Related]
22. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs. Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299 [TBL] [Abstract][Full Text] [Related]
23. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma. Sun D; Zhang C Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766 [TBL] [Abstract][Full Text] [Related]
24. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification. Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068 [TBL] [Abstract][Full Text] [Related]
25. Prognostic Value and Immune Landscapes of Four Types of RNA Modification Writer-Related LncRNAs Signature in Lung Adenocarcinoma. Qian Y; Zhang Q; Ren Y; Cao L; Zheng S; Li B; Wu X; Meng Z; Xu K J Cancer; 2024; 15(15):4818-4837. PubMed ID: 39132150 [No Abstract] [Full Text] [Related]
26. Identification and Validation of a Novel Immune-Related Four-lncRNA Signature for Lung Adenocarcinoma. Wang J; Yin X; Zhang YQ; Ji X Front Genet; 2021; 12():639254. PubMed ID: 33708243 [TBL] [Abstract][Full Text] [Related]
27. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients. Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B Front Genet; 2022; 13():966896. PubMed ID: 36186456 [No Abstract] [Full Text] [Related]
28. Identification of Fatty Acid Metabolism-Related lncRNAs as Biomarkers for Clinical Prognosis and Immunotherapy Response in Patients With Lung Adenocarcinoma. Wang H; Cui J; Yu J; Huang J; Li M Front Genet; 2022; 13():855940. PubMed ID: 35464865 [TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Genomic Instability of m Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906 [No Abstract] [Full Text] [Related]
30. A Seven Immune-Related lncRNAs Model to Increase the Predicted Value of Lung Adenocarcinoma. Li JP; Li R; Liu X; Huo C; Liu TT; Yao J; Qu YQ Front Oncol; 2020; 10():560779. PubMed ID: 33163400 [TBL] [Abstract][Full Text] [Related]
31. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma. Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758 [TBL] [Abstract][Full Text] [Related]
32. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma. Hu J; Wang T; Chen Q Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848 [TBL] [Abstract][Full Text] [Related]
33. Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs. Liang P; Li J; Chen J; Lu J; Hao Z; Shi J; Chang Q; Zeng Z Sci Rep; 2022 May; 12(1):7162. PubMed ID: 35504892 [TBL] [Abstract][Full Text] [Related]
34. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma. Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461 [TBL] [Abstract][Full Text] [Related]
35. Construction of a Ferroptosis-Related Long Non-coding RNA Prognostic Signature and Competing Endogenous RNA Network in Lung Adenocarcinoma. Fei X; Hu C; Wang X; Lu C; Chen H; Sun B; Li C Front Cell Dev Biol; 2021; 9():751490. PubMed ID: 34820377 [TBL] [Abstract][Full Text] [Related]
36. A novel tumor mutation-related long non-coding RNA signature for predicting overall survival and immunotherapy response in lung adenocarcinoma. Chen W; Liao C; Xiang X; Li H; Wu Q; Li W; Ma Q; Chen N; Chen B; Li G Heliyon; 2024 Apr; 10(7):e28670. PubMed ID: 38586420 [TBL] [Abstract][Full Text] [Related]
37. Identification of novel prognostic model based on homologous recombination deficiency associated lncRNAs in lung adenocarcinoma. Liu X; Wang T; Ren Z; Feng C; Tian X Heliyon; 2023 Apr; 9(4):e14811. PubMed ID: 37089382 [TBL] [Abstract][Full Text] [Related]
38. An Immune-Related lncRNA Expression Profile to Improve Prognosis Prediction for Lung Adenocarcinoma: From Bioinformatics to Clinical Word. Zhang B; Wang R; Li K; Peng Z; Liu D; Zhang Y; Zhou L Front Oncol; 2021; 11():671341. PubMed ID: 33968781 [TBL] [Abstract][Full Text] [Related]
39. Identification of a apoptosis-related LncRNA signature to improve prognosis prediction and immunotherapy response in lung adenocarcinoma patients. Luo T; Yu S; Ouyang J; Zeng F; Gao L; Huang S; Wang X Front Genet; 2022; 13():946939. PubMed ID: 36171881 [TBL] [Abstract][Full Text] [Related]
40. Construction and experimental validation of a necroptosis-related lncRNA signature as a prognostic model and immune-landscape predictor for lung adenocarcinoma. Zhang T; Hei R; Huang Y; Shao J; Zhang M; Feng K; Qian W; Li S; Jin F; Chen Y Am J Cancer Res; 2023; 13(9):4418-4433. PubMed ID: 37818057 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]